Skip to content
Trial Eligibility
Menu

Interrogation of Exosome-mediated Intercellular Signaling in Patients With Pancreatic Cancer

NCT02393703

This study is recruiting at 1 US site in 1 state, according to its ClinicalTrials.gov record last updated .

Summary

The purpose of this study is to isolate and analyze exosomes, which are tiny carriers of important proteins and nucleic acids that serve as messenger systems in the blood and tissue. Blood and tissue from patients with pancreatic cancer will be compared with blood and tissue from patients with noncancerous pancreatic disease. Including patients without cancer will allow the investigators to establish "normal" values, which currently do not exist. The investigators will then look to see whether exosome activity has a connection to disease recurrence and outcomes in patients.

Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov

Conditions studied

  • Pancreatic Cancer
  • Benign Pancreatic Disease

Eligibility basics and study details

Study type
Observational
Phase
Not applicable
Ages
18 years and older
Sex
All
Healthy volunteers
Accepted
Sponsor
Memorial Sloan Kettering Cancer Center
Last updated on ClinicalTrials.gov
February 9, 2026

These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.

US recruiting sites

New York · 1

  • Memorial Sloan Kettering Cancer Center · New York, NY

Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.